MENLO PARK, Calif., Oct. 26, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it will release third quarter 2011 financial results after the market closes on Tuesday, Nov. 1, 2011. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT, to discuss its results.
The conference call will be available via a live webcast and via telephone. The dial-in number from the United States and Canada is 888-778-9067 and the conference code is 8045250. For calls from other countries, the dial-in number is 913-312-0408.
The webcast can be accessed via the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market. Gralise™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform(R) drug delivery technology. Additional information about Depomed may be found on its website, http://www.depomed.com.
The Depomed, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7529